To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

Ezlopitant
Clinical data
Other namesCJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine[1]
Routes of
administration
By mouth
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
ExcretionUrine (32%), Feces (51%)
Identifiers
  • (2S,3S)-2-Benzhydryl-N-[(5-isopropyl-2-methoxy-phenyl)methyl]quinuclidin-3-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC31H38N2O
Molar mass454.658 g·mol−1
3D model (JSmol)
  • COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)C
  • InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1
  • Key:XPNMCDYOYIKVGB-CONSDPRKSA-N

Ezlopitant (INN,[1] code name CJ-11,974) is an NK1 receptor antagonist.[2][3][4] It has antiemetic and antinociceptive effects.[5][6] Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.[2]

See also

References

  1. ^ a b "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 44" (PDF). World Health Organization. pp. 194–5. Retrieved 17 November 2016.
  2. ^ a b Evangelista S (October 2001). "Eziopitant. Pfizer". Current Opinion in Investigational Drugs. 2 (10): 1441–3. PMID 11890362.
  3. ^ Diemunsch P, Grélot L (September 2000). "Potential of substance P antagonists as antiemetics". Drugs. 60 (3): 533–46. doi:10.2165/00003495-200060030-00002. PMID 11030465. S2CID 25136161.
  4. ^ Giardina GA, Gagliardi S, Martinelli M (August 2003). "Antagonists at the neurokinin receptors--recent patent literature". IDrugs: The Investigational Drugs Journal. 6 (8): 758–72. PMID 12917772.
  5. ^ Tsuchiya M, Fujiwara Y, Kanai Y, et al. (November 2002). "Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret". Pharmacology. 66 (3): 144–52. doi:10.1159/000063796. PMID 12372904. S2CID 37936941.
  6. ^ Tsuchiya M, Sakakibara A, Yamamoto M (January 2005). "A tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behaviour in the rat". European Journal of Pharmacology. 507 (1–3): 29–34. doi:10.1016/j.ejphar.2004.11.028. PMID 15659291.


This page was last edited on 23 January 2023, at 11:28
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.